Skip to content
Menu

Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3

Benzinga Newsdesk 8 months ago

NewsPrice TargetInitiationAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.

Read at benzinga.com